CSF3 and lymphoma: In the lymphoma trial [84] a significantly higher proportion of patients (59.3%) achieved optimal CD34+ cell collection (≥5 × 106/kg) in the G-CSF plus plerixafor arm compared to the G-CSF plus placebo arm (19.6%).